Ignite Creation Date:
2025-12-24 @ 11:04 PM
Ignite Modification Date:
2025-12-31 @ 3:07 PM
Study NCT ID:
NCT00726869
Status:
TERMINATED
Last Update Posted:
2012-08-23
First Post:
2008-07-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.
Sponsor:
Abbott
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2008-05
Start Date Type:
None
Primary Completion Date:
2012-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2012-03
Completion Date Type:
ACTUAL
First Submit Date:
2008-07-29
First Submit QC Date:
None
Study First Post Date:
2008-08-01
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2012-08-22
Last Update Post Date:
2012-08-23
Last Update Post Date Type:
ESTIMATED